title: Mycoplasma fermentans and TNF-beta interact to amplify immune-modulating cytokines in human lung fibroblasts.
abstract: Mycoplasma can establish latent infections and are associated with arthritis, leukemia, and chronic lung disease. We developed an experimental model in which lung cells are deliberately infected with Mycoplasma fermentans. Human lung fibroblasts (HLF) were exposed to live M. fermentans and immune-modulating cytokine release was assessed with and without known inducers of cytokine production. M. fermentans increased IL-6, IL-8/CXCL8, MCP-1/CCL2, and Gro-alpha/CXCL1 production. M. fermentans interacted with TNF-beta to release more IL-6, CXCL8, and CXCL1 than predicted by the responses to either stimulus alone. The effects of live infection were recapitulated by exposure to M. fermentans-derived macrophage-activating lipopeptide-2 (MALP-2), a Toll-like receptor-2- and receptor-6-specific ligand. The synergistic effect of combined stimuli was more pronounced with prolonged incubations. Preexposure to TNF-beta sensitized the cells to subsequent MALP-2 challenge, but preexposure to MALP-2 did not alter the IL-6 response to TNF-beta. Exposure to M. fermentans or MALP-2 did not enhance nuclear localization, DNA binding, or transcriptional activity of NF-kappaB and did not modulate early NF-kappaB activation in response to TNF-beta. Application of specific inhibitors of various MAPKs suggested that p38 and JNK/stress-activated protein kinase were involved in early IL-6 release after exposure to TNF-beta and M. fermentans, respectively. The combined response to M. fermentans and TNF-beta, however, was uniquely sensitive to delayed application of SP-600125, suggesting that JNK/stress-activated protein kinase contributes to the amplification of IL-6 release. Thus M. fermentans interacts with stimuli such as TNF-beta to amplify lung cell production of immune-modulating cytokines. The mechanisms accounting for this interaction can now be dissected with the use of this in vitro model.
authors.affiliation: Department of Environmental and Occupational Health, Center for Free Radical and Antioxidant Health, University of Pittsburgh Graduate School of Public Health, College of Medicine, Pittsburgh, PA 15219-3130, USA. fabs@pitt.edu
authors.forename: James P
authors.initials: JP
authors.lastname: Fabisiak
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.forename: Robyn G
authors.initials: RG
authors.lastname: Thomson
authors.forename: Robert M
authors.initials: RM
authors.lastname: Strieter
authors.forename: Simon C
authors.initials: SC
authors.lastname: Watkins
authors.forename: James H
authors.initials: JH
authors.lastname: Dauber
mesh_terms: D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism*; D055666:Lipopeptides; D008168:Lung / Q000187:drug effects / Q000378:metabolism*; D008171:Lung Diseases / Q000378:metabolism*; D008233:Lymphotoxin-alpha / Q000494:pharmacology*; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology; D009175:Mycoplasma Infections / Q000378:metabolism*; D016858:Mycoplasma fermentans; D016328:NF-kappa B / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D051195:Toll-Like Receptor 2 / Q000819:agonists; D051216:Toll-Like Receptor 6 / Q000819:agonists
chemical_list: D016207:Cytokines; D007155:Immunologic Factors; D055666:Lipopeptides; D008233:Lymphotoxin-alpha; D016328:NF-kappa B; D009842:Oligopeptides; D051195:Toll-Like Receptor 2; D051216:Toll-Like Receptor 6; C106335:macrophage stimulatory lipopeptide 2; D020928:Mitogen-Activated Protein Kinases